FDA approves Savient's Krystexxa

The FDA approved a BLA from Savient Pharmaceuticals Inc. (NASDAQ:SVNT) for Krystexxa pegloticase to treat chronic gout in adults refractory to conventional therapy. The approval includes a boxed warni...